790 related articles for article (PubMed ID: 29858436)
1. Non-alcoholic fatty liver disease.
Maurice J; Manousou P
Clin Med (Lond); 2018 Jun; 18(3):245-250. PubMed ID: 29858436
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and natural history of non-alcoholic fatty liver disease.
Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
9. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
10. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
[TBL] [Abstract][Full Text] [Related]
11. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
Westfall E; Jeske R; Bader AR
Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
[TBL] [Abstract][Full Text] [Related]
13. Identification of high-risk subjects in nonalcoholic fatty liver disease.
Stern C; Castera L
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S196-S206. PubMed ID: 36472050
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
Morrison M; Hughes HY; Naggie S; Syn WK
Dig Dis Sci; 2019 Dec; 64(12):3394-3401. PubMed ID: 31643035
[TBL] [Abstract][Full Text] [Related]
15. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
16. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of non-alcoholic fatty liver disease.
Jennison E; Patel J; Scorletti E; Byrne CD
Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
20. Imaging biomarkers of NAFLD, NASH, and fibrosis.
Ajmera V; Loomba R
Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
